Please login to the form below

Not currently logged in
Email:
Password:

Konstantin Linnik to head IP strategy at Idea Pharma

Former senior corporate counsel at Pfizer joins clinical stage strategy consultancy as general counsel and principal IP strategist

Konstantin Linnik - Idea PharmaIdea Pharma has appointed former senior corporate counsel at Pfizer Konstantin Linnik as its general counsel and principal intellectual property (IP) strategist.

Idea, which specialises in advising a company's strategy at the phase II stage of development, said Linnink will lead IP inputs into whole product design, giving insight into the potential opportunities for early phase assets and advising on how to improve developmental products.

The appointment is also expected to expand Idea's portfolio of clients to medium-sized pharma companies, and also give the company a base in Boston, US.

Linnik, who will join from Boston law firm Nutter McClennen and Fish LLP, said Idea's focus on distinct elements such as IP during early phase development influenced his decision to join the company.

He said: “A small change in product concept, that produces a better medicine, one with even six months more protection, can make billions of dollars difference over the lifecycle.”

Mike Rea, CEO of Idea, said: “The fantastic thing about Konstantin is that he gets it - that the role of invention isn't over when someone comes up with a pathway and a molecule.”

20th December 2011

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

The immunotherapy knowledge gap: keeping the patient at the heart of cancer treatment
Advances in cancer treatment are frequent, but how much do we actually understand about these new treatments?...
Value is in the eye of the customer. Co-creation is a bridge to value.
We conducted 16 hours of qualitative interviews with HCPs and Senior Pharma industry leaders in the UK, supported with in-depth industry scanning. Our interviews reveal important insights about the tensions...
Partnering with Patients and Caregivers in Clinical Research
...